Natural killer cells modulation in hematological malignancies

Hematological malignancies (HM) treatment improved over the last years resulting in increased achievement of complete or partial remission, but unfortunately high relapse rates are still observed, due to remaining minimal residual disease. Therefore, sustainment of long-term remission is crucial, us...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 4; no. 4; p. 459
Main Authors Baier, Céline, Fino, Aurore, Sanchez, Carole, Farnault, Laure, Rihet, Pascal, Kahn-Perlès, Brigitte, Costello, Régis T
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers 01.01.2013
Frontiers Media S.A
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Hematological malignancies (HM) treatment improved over the last years resulting in increased achievement of complete or partial remission, but unfortunately high relapse rates are still observed, due to remaining minimal residual disease. Therefore, sustainment of long-term remission is crucial, using either drug maintenance treatment or by boosting or prolonging an immune response. Immune system has a key role in tumor surveillance. Nonetheless, tumor-cells evade the specific T-lymphocyte mediated immune surveillance using many mechanisms but especially by the down-regulation of the expression of HLA class I antigens. In theory, these tumor-cells lacking normal expression of HLA class I molecules should be destroyed by natural killer (NK) cells, according to the missing-self hypothesis. NK cells, at the frontier of innate and adaptive immune system, have a central role in tumor-cells surveillance as demonstrated in the setting of allogenic stem cell transplantation. Nevertheless, tumors develop various mechanisms to escape from NK innate immune pressure. Abnormal NK cytolytic functions have been described in many HM. We present here various mechanisms involved in the escape of HM from NK-cell surveillance, i.e., NK-cells quantitative and qualitative abnormalities.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Massimo Vitale, IRCCS A.O.U. S.Martino-IST, Italy
This article was submitted to NK Cell Biology, a section of the journal Frontiers in Immunology.
Reviewed by: Laurel L. Lenz, National Jewish Health, USA; Jacques Zimmer, Centre de Recherche Public de la Santé, Luxembourg; Nicolas Dulphy, Universite Paris Diderot, France; Renato Zambello, Padova University School of Medicine, Italy
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2013.00459